5-deoxy-2,3-O-isopropylidene-β-D-ribofuranosyl chloride | 316166-19-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-deoxy-2,3-O-isopropylidene-β-D-ribofuranosyl chloride
• 英文别名: (3aR,4S,6R,6aR)-4-chloro-2,2,6-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole
• CAS: 316166-19-5
• 化学式: C₈H₁₃ClO₃
• 分子量: 192.642
• InChiKey: FIFLTGVPWDDVHG-DBRKOABJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-deoxy-2,3-O-isopropylidene-β-D-ribofuranosyl chloride 、 4-benzyloxy-7H-pyrrolo[2,3-d]pyrimidine 在 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 生成 4-Benzyloxy-7-((3aR,4S,6R,6aR)-2,2,6-trimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine 、 4-Benzyloxy-7-((3aR,4R,6R,6aR)-2,2,6-trimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  β-Selective nucleoside analog synthesis from chlorofuranoses

  摘要：

  A method to form glycosyl linkages between nitrogen-containing heterocycles and appropriately protected furanoses is described. The method is highly beta-selective, operationally simple, and utilizes readily available reagents making the process amenable to scaleup. Representative examples of coupling between chlorofuranoses and purines or pyrrolopyrimidines are described. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(00)01429-5
• 作为产物：
  描述：

  5-deoxy-2,3-O-isopropylidene-α-D-ribofuranosyl chloride 以 氘代二甲亚砜 为溶剂， 反应 3.0h， 生成 5-deoxy-2,3-O-isopropylidene-β-D-ribofuranosyl chloride
  参考文献：
  名称：

  腺苷激酶抑制剂。1. 5-碘代结核菌素类似物的合成，酶抑制和抗癫痫活性。

  摘要：

  腺苷受体激动剂产生多种治疗上有用的药理学。然而，迄今为止，由于剂量限制的副作用，它们未能成功进行临床开发。腺苷激酶抑制剂（AKIs）代表了另一种策略，因为AKIs可以以更多位点和事件特异性的方式提高局部腺苷水平，从而以更大的治疗窗口引发所需的药理作用。从5-碘代小球蛋白（IC50 = 0.026 microM）和5'-氨基-5'-脱氧腺苷（IC50 = 0.17 microM）作为分离的人AK的主要抑制剂开始，各种吡咯并[2,3-d]嘧啶核苷类似物通过使用钠盐介导的糖基化方法将5-取代的4-取代的4-氯吡咯并[2,3-d]嘧啶碱基与核糖类似物偶联来设计和制备。5'-氨基-5' 发现5-溴和5-碘结核菌素的β-脱氧类似物是迄今为止报道的最有效的AKI（IC50S <0.001 microM）。在大鼠最大电击（MES）诱发的癫痫发作试验中，几种有效的AKIs表现出抗惊厥活性。

  DOI：

  10.1021/jm000024g

文献信息

• Adenosine Kinase Inhibitors. 2. Synthesis, Enzyme Inhibition, and Antiseizure Activity of Diaryltubercidin Analogues
  作者：Bheemarao G. Ugarkar、Angelo J. Castellino、Jay M. DaRe、Joseph J. Kopcho、James B. Wiesner、Juergen M. Schanzer、Mark D. Erion

  DOI：10.1021/jm0000259

  日期：2000.7.1

  In the preceding article (Ugarkar et al. J. Med. Chem. 2000, 43) we reported that analogues of tubercidin are potent adenosine kinase (AK) inhibitors with antiseizure activity in the rat maximum electroshock (MES) model. Despite the discovery of several highly potent AK inhibitors (AKIs), e.g., 5'-amino-5'-deoxy-5-iodotubercidin (1c) (IC50 = 0.0006 mu M), no compounds were identified that exhibited a safety, efficacy, and side effect profile suitable for further development. In this article, we demonstrate that substitution of the tubercidin molecule with aromatic rings at the N4- and the C5-positions not only retains AKI potency but also improves in vivo activity. Synthesis of such compounds entailed transformation of 4-arylanlino-5-iodotubercidin analogues to their corresponding 5-aryl derivatives via the Suzuki reaction. Alternatively, 4-N-suylamino-5-arylpyrrolo[2,3-d]pyrimdine bases were constructed and then glycosylated with appropriately protected alpha-ribofuranosyl chlorides using a phase-transfer catalyst. Several compounds exhibited potent activity in the rat MES seizure assay with ED(50)s less than or equal to 2.0 mg/kg, ip, and showed relatively mild side effects.
• Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition, and Antiseizure Activity of 5-Iodotubercidin Analogues
  作者：Bheemarao G. Ugarkar、Jay M. DaRe、Joseph J. Kopcho、Clinton E. Browne、Juergen M. Schanzer、James B. Wiesner、Mark D. Erion

  DOI：10.1021/jm000024g

  日期：2000.7.1

  side effects. Adenosine kinase inhibitors (AKIs) represent an alternative strategy, since AKIs may raise local adenosine levels in a more site- and event-specific manner and thereby elicit the desired pharmacology with a greater therapeutic window. Starting with 5-iodotubercidin (IC50 = 0.026 microM) and 5'-amino-5'-deoxyadenosine (IC50 = 0.17 microM) as lead inhibitors of the isolated human AK, a variety

  腺苷受体激动剂产生多种治疗上有用的药理学。然而，迄今为止，由于剂量限制的副作用，它们未能成功进行临床开发。腺苷激酶抑制剂（AKIs）代表了另一种策略，因为AKIs可以以更多位点和事件特异性的方式提高局部腺苷水平，从而以更大的治疗窗口引发所需的药理作用。从5-碘代小球蛋白（IC50 = 0.026 microM）和5'-氨基-5'-脱氧腺苷（IC50 = 0.17 microM）作为分离的人AK的主要抑制剂开始，各种吡咯并[2,3-d]嘧啶核苷类似物通过使用钠盐介导的糖基化方法将5-取代的4-取代的4-氯吡咯并[2,3-d]嘧啶碱基与核糖类似物偶联来设计和制备。5'-氨基-5' 发现5-溴和5-碘结核菌素的β-脱氧类似物是迄今为止报道的最有效的AKI（IC50S <0.001 microM）。在大鼠最大电击（MES）诱发的癫痫发作试验中，几种有效的AKIs表现出抗惊厥活性。
• β-Selective nucleoside analog synthesis from chlorofuranoses
  作者：Robert W. Scott、Darrell E. Fox、Dawnnica K. Williams

  DOI：10.1016/s0040-4039(00)01429-5

  日期：2000.10

  A method to form glycosyl linkages between nitrogen-containing heterocycles and appropriately protected furanoses is described. The method is highly beta-selective, operationally simple, and utilizes readily available reagents making the process amenable to scaleup. Representative examples of coupling between chlorofuranoses and purines or pyrrolopyrimidines are described. (C) 2000 Published by Elsevier Science Ltd.